摘要
Metabolic(dysfunction)associated fatty liver disease(MAFLD),previously known as non-alcoholic fatty liver disease,is the most common cause of chronic liver disease worldwide.Many risk factors contribute to the pathogenesis of MAFLD with metabolic dysregulation being the final arbiter of its development and progression.MAFLD poses a substantial economic burden to societies,which based on current trends is expected to increase over time.Numerous studies have addressed various aspects of MAFLD from its risk associations to its economic and social burden and clinical diagnosis and management,as well as the molecular mechanisms linking MAFLD to end-stage liver disease and hepatocellular carcinoma.This review summarizes current understanding of the pathogenesis of MAFLD and related diseases,particularly liver cancer.Potential therapeutic agents for MAFLD and diagnostic biomarkers are discussed.
基金
JG is supported by the Robert W.Storr Bequest to the Sydney Medical Foundation,University of Sydney
and National Health and Medical Research Council of Australia(NHMRC)Program and Investigator Grants(AAP2008983,APP1053206,APP1196492)
LQ is supported by NSW Cancer Council grants(APP1145008,APP1070076).
作者简介
Corresponding author:Jacob George,Email:jacob.george@sydney.edu.au;Corresponding author:Liang Qiao,Email:liang.qiao@sydney.edu.au。
